CORDIS
EU research results

CORDIS

English EN
Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe

Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe

Objective

HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies.

Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies.

HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients.

Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies.

Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
3584 Cs Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 352 135

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 228 125

OULUN YLIOPISTO

Finland

EU Contribution

€ 726 500

UNIVERSITY OF YORK

United Kingdom

EU Contribution

€ 984 602,50

MEDICAL UNIVERSITY SOFIA

Bulgaria

EU Contribution

€ 313 687,50

UNIVERSITAET BERN

Switzerland

EU Contribution

€ 749 062,50

UNIVERSIDAD POLITECNICA DE MADRID

Spain

EU Contribution

€ 382 100

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Belgium

EU Contribution

€ 871 250

TANDVARDS-OCH LAKEMEDELSFORMANSVERKET

Sweden

EU Contribution

€ 324 000

ZORGINSTITUUT NEDERLAND

Netherlands

EU Contribution

€ 484 450

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

United Kingdom

EU Contribution

€ 808 250

SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

Hungary

EU Contribution

€ 676 912,50

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

EU Contribution

€ 728 937,50

EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION

France

EU Contribution

€ 625 907,50

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 384 855

Project information

Grant agreement ID: 825162

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.6.

  • Overall budget:

    € 9 640 775

  • EU contribution

    € 9 640 775

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands